吉林省参与COVID-19暴露后预防用药临床试验意愿的研究  

Study on willingness to participate in clinical trials of post-exposure prophylaxis for COVID-19 in Jilin Province

作　　者：李娜[1] 范吉祥[1] 邱柏红[1] 黄黎宁[1] 李紫璇[1] 吴丹 胡彦 LI Na;FAN Jixiang;QIU Baihong;HUANG Lining;LI Zixuan;WU Dan;HU Yan(Institute of HIV/AIDS and STD Prevention and Control,Jilin Provincial Center for Disease Control and Prevention(Jilin Academy of Preventive Medicine),Changchun,Jilin 130062,China)

机构地区：[1]吉林省疾病预防控制中心(吉林省预防医学科学院)艾滋病性病预防控制所,吉林长春130062

出　　处：《医学动物防制》2025年第2期195-199,共5页Journal of Medical Pest Control

基　　金：中国疾病预防控制中心省市联动参与新冠暴露后预防用药策略分析(2023GC-05F)。

摘　　要：目的了解吉林省SARS-CoV-2感染者及其密切接触者参与COVID-19暴露后预防用药临床试验的意愿及影响因素,为今后开展COVID-19暴露后预防用药临床试验提供理论依据。方法方便抽取2023年9月1日—10月15日长春市通过中国疾病预防控制信息系统报告的SARS-CoV-2感染者,通过流行病学调查招募SARS-CoV-2密切接触者(感染者∶密切接触者=1∶1),对SARS-CoV-2感染者及其密切接触者进行问卷调查。采用SPSS 22.0统计软件进行描述分析。单因素分析采用χ^(2)和矫正χ^(2)检验;多因素分析采用非条件logistic回归分析。结果不愿参与COVID-19暴露后预防用药临床试验的原因中,“不愿意当试验品”和“对COVID-19暴露后预防用药的安全性和有效性存疑”的响应率和普及率较高。logistic回归分析结果显示,参与COVID-19暴露后预防用药临床试验的意愿方面,“累计接种SARS-CoV-2疫苗针次”和“本人或亲朋是否参与过药物临床试验”是受访者参与意愿的影响因素;累计接种SARS-CoV-2疫苗针次≥4针者参与意愿高于未接种者(OR=7.260,95%CI:1.410~37.376);“本人或亲朋参与过药物临床试验”者参与意愿高于“本人或亲朋未参与过药物临床试验”者(OR=12.610,95%CI:2.084~76.296)。结论吉林省SARS-CoV-2感染者及其密切接触者参与COVID-19暴露后预防用药临床试验意愿较低,应加强临床试验认知宣传。Objective To understand the willingness and influencing factors of SARS-CoV-2 infectors and their close contacts to participate in clinical trials of post-exposure prophylaxis for COVID-19 in Jilin Province,and to provide a theoretical basis for clinical trials of post-exposure prophylaxis for COVID-19 in the future.Methods The infectors of SARS-CoV-2 reported by the Chinese disease prevention and control information system in Changchun City from September 1 to October 15,2023,were conveniently selected.The close contacts of SARS-CoV-2 were recruited through epidemiological investigation(infectors∶close contacts=1∶1),the SARS-CoV-2 infectors and their close contacts were investigated by questionnaire.SPSS 22.0 statistical software was used for descriptive analysis.Univariate analysis was conducted using the χ^(2) and corrected χ^(2) tests.Multifactoral analysis was performed using unconditional logistic regression analysis.Results Among the reasons for not wanting to participate in clinical trials of post-exposure prophylaxis for COVID-19,the response rates and prevalence rates of"not willing to be a test subject"and"doubtful about the safety and efficacy of post-exposure prophylaxis for COVID-19"were relatively high.The results of logistic regression analysis showed that in terms of willingness to participate in clinical trials of post-exposure prophylaxis for COVID-19,"the cumulative number of doses of SARS-CoV-2 vaccine"and"whether oneself or my relatives or friends have participated in drug clinical trials"were the influencing factors of respondents′willingness to participate.Those who cumulative received≥4 doses of the SARS-CoV-2 vaccine were more willing to participate than those who did not(OR=7.260,95%CI:1.410-37.376).Those who"oneself or my relatives or friends have participated in drug clinical trials"were more willing to participate than those who"oneself or my relatives have not participated in drug clinical trials"(OR=12.610,95%CI:2.084-76.296).Conclusion The willingness of SARS-CoV-2 infec

关 键 词：COVID-19 暴露后预防用药 临床试验 意愿 影响因素 

分 类 号：R511[医药卫生—内科学]